Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial

PLoS Neglected Tropical Diseases

Volumn 10, Issue 9, 2016, Pages

  Barda, Beatrice ^a,b   Coulibaly, Jean T ^a,b,c,d   Puchkov, Maxim ^b   Huwyler, Jörg ^b   Hattendorf, Jan ^a   Keiser, Jennifer ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^d CENTRE SUISSE DE RECHERCHES SCIENTIFIQUES EN CÔTE D'IVOIRE   (Côte d’Ivoire)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; MOXIDECTIN; PRAZIQUANTEL; SYNRIAM; UNCLASSIFIED DRUG; ANTHELMINTIC AGENT; ANTIMALARIAL AGENT; MACROLIDE; MILBEMYCIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS MANSONI; SCHOOL CHILD; SINGLE BLIND PROCEDURE; ANIMAL; CLINICAL TRIAL; COINFECTION; COMBINATION DRUG THERAPY; COTE D'IVOIRE; DRUG EFFECTS; PARASITE IDENTIFICATION; TREATMENT OUTCOME;

ADOLESCENT; ANIMALS; ANTHELMINTICS; ANTIMALARIALS; CHILD; COINFECTION; COTE D'IVOIRE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MACROLIDES; MALE; PARASITE EGG COUNT; PRAZIQUANTEL; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS MANSONI; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84991741353     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005008     Document Type: Article

References (39)

1. Colley DG, Bustinduy AL, Secor WE, King CH, Human schistosomiasis. Lancet. 2014;383: 2253–2264. doi: 10.1016/S0140-6736(13)61949-224698483
2. GBD 2013 DALYs and HALE CollaboratorsMurray CJL, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet2015;386: 2145–2191. doi: 10.1016/S0140-6736(15)61340-X26321261
3. Utzinger J, N’Goran EK, Caffrey CR, Keiser J, From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop. 2011;120Suppl 1: S121–137. doi: 10.1016/j.actatropica.2010.08.02020831855
4. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3. doi: 10.1371/journal.pntd.0000504
5. Keiser J, Silué KD, Adiossan LK, N’Guessan NA, Monsan N, Utzinger J, et al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: A randomized, exploratory, open-label trial. PLoS Negl Trop Dis. 2014;8. doi: 10.1371/journal.pntd.0002975
6. Pedrique B, Strub-Wourgaft N, Some C, Olliaro P, Trouiller P, Ford N, et al. The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment. Lancet Glob Health. 2013;1: e371–379. doi: 10.1016/S2214-109X(13)70078-025104602
7. Le WJ, You JQ, Yang YQ, Mei JY, Guo HF, Yang HZ, et al. Studies on the efficacy of artemether in experimental schistosomiasis. Acta Pharmaceutica Sinica. 1982;17: 187–193. 7115549
8. Ho WE, Peh HY, Chan TK, Wong WSF, Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 2014;142: 126–139. doi: 10.1016/j.pharmthera.2013.12.00124316259
9. Keiser J, Utzinger J, Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis. 2007;20: 605–612. doi: 10.1097/QCO.0b013e3282f19ec417975411
10. Xiao SH, Utzinger J, Tanner M, Keiser J, Xue J, Advances with the Chinese anthelminthic drug tribendimidine in clinical trials and laboratory investigations. Acta Trop. 2013;126: 115–126. doi: 10.1016/j.actatropica.2013.01.00923352956
11. Xiao SH, Keiser J, Chollet J, Utzinger J, Dong Y, Endriss Y, et al. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother. 2007;51: 1440–1445. doi: 10.1128/AAC.01537-0617283188
12. Gautam A, Ahmed T, Sharma P, Varshney B, Kothari M, Saha N, et al. Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with P. falciparum malaria. J Clin Pharmacol. 2011;51: 1519–1528. doi: 10.1177/009127001038557821148048
13. Saha N, Moehrle JJ, Zutshi A, Sharma P, Kaur P, Iyer SS, Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects. J Clin Pharmacol. 2014;54: 386–393. doi: 10.1002/jcph.23224242999
14. Patil C, Katare S, Baig M, Doifode S, Fixed dose combination of arterolane and piperaquine: a newer prospect in antimalarial therapy. Ann Med Health Sci Res. 2014;4: 466–471. doi: 10.4103/2141-9248.13927025221689
15. Mossallam SF, Amer EI, El-Faham MH, Efficacy of SynriamTM, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of Schistosoma mansoni. Acta Trop. 2015;143: 36–46. doi: 10.1016/j.actatropica.2014.12.00525530543
16. Genchi C, Poglayen G, Kramer LH, Venco L, Agostini A, Efficacy of moxidectin for the prevention of adult heartworm (Dirofilaria immitis) infection in dogs. Parassitologia. 2001;43: 139–141. 11921542
17. Turner HC, Walker M, Attah SK, Opoku NO, Awadzi K, Kuesel AC, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8: 167. doi: 10.1186/s13071-015-0779-425889256
18. Attah SK. Effect of a single dose of 8 mg moxidectin or 150 µg/kg ivermectin on intestinal helminths in participants of a clinical trial conducted in Northeast DRC, Liberia and Ghana. [Internet]. [cited 17 Mar 2016]. Available: https://www.researchgate.net/publication/270214613_Effect_of_a_single_dose_of_8_mg_moxidectin_or_150_gkg_ivermectin_on_intestinal_helminths_in_participants_of_a_clinical_trial_conducted_in_Northeast_DRC_Liberia_and_Ghana
19. Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC, A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8: e2953. doi: 10.1371/journal.pntd.000295324968000
20. Coulibaly JT, N’gbesso YK, Knopp S, Keiser J, N’Goran EK, Utzinger J, Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Negl Trop Dis. 2012;6: e1917. doi: 10.1371/journal.pntd.000191723236526
21. Katz N, Chaves A, Pellegrino J, A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop São Paulo. 1972;14: 397–400. 4675644
22. Schmidt B, Proof of Principle studies. Epilepsy Res. 2006;68: 48–52. doi: 10.1016/j.eplepsyres.2005.09.01916377153
23. Keiser J, N’Goran EK, Singer BH, Lengeler C, Tanner M, Utzinger J, Association between Schistosoma mansoni and hookworm infections among schoolchildren in Côte d’Ivoire. Acta Trop. 2002;84: 31–41. 12387908
24. Utzinger J, N’Goran EK, Esse Aya CM, Acka Adjoua C, Lohourignon KL, Tanner M, et al. Schistosoma mansoni, intestinal parasites and perceived morbidity indicators in schoolchildren in a rural endemic area of western Côte d’Ivoire. Trop Med Int Health TM IH. 1998;3: 711–720. 9754666
25. Speich B, Ame SM, Ali SM, Alles R, Huwyler J, Hattendorf J, et al. Oxantel pamoate-albendazole for Trichuris trichiura infection. N Engl J Med. 2014;370: 610–620. doi: 10.1056/NEJMoa130195624521107
26. World Health OrganisationPrevention and control of schistosomiasis and soil-transmitted helminthiasis. Report of a WHO Expert Committee. WHO Technical Report Series912. World Health Organisation, Geneva, 2002.
27. Panic G, Duthaler U, Speich B, Keiser J, Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist. 2014;4: 185–200. doi: 10.1016/j.ijpddr.2014.07.00225516827
28. Verma M, Pathak M, Shahab M, Singh K, Mitra K, Misra-Bhattacharya S, Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models. Folia Parasitol (Praha). 2014;61: 561–570.
29. Zwang J, Olliaro PL, Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis. 2014;8: e3286. doi: 10.1371/journal.pntd.000328625412105
30. Olliaro PL, Vaillant M, Diawara A, Coulibaly JT, Garba A, Keiser J, et al. Toward measuring Schistosoma response to praziquantel treatment with appropriate descriptors of egg excretion. PLoS Negl Trop Dis. 2015;9. doi: 10.1371/journal.pntd.0003821
31. Stothard JR, Sousa-Figueiredo JC, Navaratnam AMD, Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis. Expert Rev Anti Infect Ther. 2013;11: 733–752. doi: 10.1586/14787210.2013.81193123879611
32. Tchuem Tchuenté LA, Shaw DJ, Polla L, Cioli D, Vercruysse J, Efficacy of praziquantel against Schistosoma haematobium infection in children. Am J Trop Med Hyg. 2004;71: 778–782. 15642971
33. Liu YX, Wu W, Liang YJ, Jie ZL, Wang H, Wang W, et al. New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China. Mol Basel Switz. 2014;19: 15058–15074. doi: 10.3390/molecules190915058
34. Liu R, Dong HF, Guo Y, Zhao QP, Jiang MS, Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit Vectors. 2011;4: 201. doi: 10.1186/1756-3305-4-20122004571
35. Wang W, Li TY, Ji Y, Qu GL, Qian YL, Li HJ, et al. Efficacy of artemether and artesunate in mice infected with praziquantel non-susceptible isolate of Schistosoma japonicum. Parasitol Res. 2014;113: 925–931. doi: 10.1007/s00436-013-3724-524326467
36. Wikman-Jorgensen PE, Henríquez-Camacho CA, Serrano-Villar S, Pérez-Molina JA, The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: a systematic review and meta-analysis. Pathog Glob Health. 2012;106: 397–404. doi: 10.1179/2047773212Y.000000003823265611
37. King CH, Bertsch D, Meta-analysis of urine heme dipstick diagnosis of Schistosoma haematobium infection, including low-prevalence and previously-treated populations. PLoS Negl Trop Dis. 2013;7: e2431. doi: 10.1371/journal.pntd.000243124069486
38. Toure OA, Valecha N, Tshefu AK, Thompson R, Krudsood S, Gaye O, et al. A Phase 3, double-blind, randomized study of arterolane maleate–piperaquine phosphate vs artemether–lumefantrine for falciparum malaria in adolescent and adult patients in Asia and Africa. Clin Infect Dis. 2016;62: 964–971. doi: 10.1093/cid/ciw02926908796
39. Valecha N, Krudsood S, Tangpukdee N, Mohanty S, Sharma SK, Tyagi PK, et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: A comparative, multicenter, randomized clinical trial. Clin Infect Dis. 2012;55: 663–671. doi: 10.1093/cid/cis47522586253